# Hope Biosciences Research Foundation trials: 26 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with Hope Biosciences Research Foundation as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Hope Biosciences Research Foundation: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hope-biosciences-research-foundation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 20, 2025 | NCT07238062 | "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope... | Hope Biosciences Research Foundation | Not applicable | Available | Multiple System Atrophy | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238062) |
| September 10, 2025 | NCT07164482 | Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or... | Hope Biosciences Research Foundation | Not applicable | No longer available | Brain Injury | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07164482) |
| July 22, 2025 | NCT07077746 | HB-adMSCs for the Treatment of Crohn's Disease | Hope Biosciences Research Foundation | Phase 2 | Recruiting | Crohn Disease (CD) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077746) |
| January 30, 2025 | NCT06800404 | "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" | Hope Biosciences Research Foundation | Phase 2 | Active not recruiting | Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06800404) |
| October 2, 2024 | NCT06623240 | HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis | Hope Biosciences Research Foundation | Phase 2 | Withdrawn | Juvenile Idiopathic Arthritis (JIA) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06623240) |
| September 28, 2023 | NCT06056427 | Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease | Hope Biosciences Research Foundation | Not applicable | No longer available | Parkinson Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06056427) |
| December 13, 2021 | NCT05154851 | HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy. | Hope Biosciences Research Foundation | Not applicable | No longer available | Congenital Muscular Dystrophy Due to Lamin A/C Mutation | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05154851) |
| November 19, 2021 | NCT05126563 | Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome | Hope Biosciences Research Foundation | Phase 2 | Completed | Post COVID-19 Syndrome | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05126563) |
| November 11, 2021 | NCT05116540 | Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis | Hope Biosciences Research Foundation | Phase 2 | Completed | Multiple Sclerosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05116540) |
| August 6, 2021 | NCT04995081 | Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) | Hope Biosciences Research Foundation | Phase 2 | Completed | Parkinson Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04995081) |
| June 16, 2021 | NCT04928287 | Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) | Hope Biosciences Research Foundation | Phase 2 | Completed | Parkinson Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04928287) |
| May 28, 2021 | NCT04907188 | Individual Patient Expanded Access IND for the Treatment of Stroke | Hope Biosciences Research Foundation | Not applicable | No longer available | Stroke, Stroke, Ischemic | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04907188) |
| May 28, 2021 | NCT04907175 | Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE) | Hope Biosciences Research Foundation | Not applicable | No longer available | System; Lupus Erythematosus | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04907175) |
| April 1, 2021 | NCT04825626 | An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Hope Biosciences Research Foundation | Not applicable | No longer available | Chronic Inflammatory Demyelinating Polyneuropathy | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04825626) |
| April 1, 2021 | NCT04825613 | "Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis" | Hope Biosciences Research Foundation | Not applicable | No longer available | Primary Lateral Sclerosis, Adult, 1 | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04825613) |
| March 15, 2021 | NCT04798066 | Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome | Hope Biosciences Research Foundation | Not applicable | No longer available | Post COVID-19 Syndrome | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04798066) |
| February 26, 2021 | NCT04772378 | Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease. | Hope Biosciences Research Foundation | Not applicable | No longer available | Parkinson Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04772378) |
| January 15, 2021 | NCT04711811 | Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain. | Hope Biosciences Research Foundation | Not applicable | No longer available | Chronic Pain | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04711811) |
| October 27, 2020 | NCT04604288 | Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain. | Hope Biosciences Research Foundation | Not applicable | No longer available | Knee Pain Chronic, Osteo Arthritis Knee | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04604288) |
| August 17, 2020 | NCT04514952 | Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis | Hope Biosciences Research Foundation | Not applicable | No longer available | Amyotrophic Lateral Sclerosis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04514952) |
| April 24, 2020 | NCT04362189 | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | Hope Biosciences Research Foundation | Phase 2 | Terminated | COVID-19 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04362189) |
| April 16, 2020 | NCT04349631 | A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 | Hope Biosciences Research Foundation | Phase 2 | Completed | COVID-19 | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04349631) |
| April 16, 2020 | NCT04348435 | A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. | Hope Biosciences Research Foundation | Phase 2 | Completed | COVID-19 | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04348435) |
| August 22, 2019 | NCT04064983 | Individual Patient Expanded Access IND to Treat Polyneuropathy | Hope Biosciences Research Foundation | Not applicable | No longer available | Polyneuropathies | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04064983) |
| August 22, 2019 | NCT04064957 | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury | Hope Biosciences Research Foundation | Not applicable | No longer available | Spinal Cord Injuries | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04064957) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 10 |
| Not applicable | 16 |

## By status

| Status | Trials |
| --- | --- |
| No longer available | 15 |
| Completed | 6 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Terminated | 1 |
| Active not recruiting | 1 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 4 |
| COVID-19 | 4 |
| Coronavirus Infections | 3 |
| Pain | 2 |
| Sclerosis | 2 |
| Multiple Sclerosis | 2 |
| Post-Acute COVID-19 Syndrome | 2 |
| Lupus Erythematosus, Systemic | 1 |
| Arthritis, Juvenile | 1 |
| Arthritis | 1 |
| Brain Injuries | 1 |
| Stroke | 1 |
| Ischemic Stroke | 1 |
| Ischemia | 1 |
| Muscular Dystrophy, Congenital, Lmna-Related | 1 |
| Muscular Dystrophies | 1 |
| Polyneuropathies | 1 |
| Neuralgia | 1 |
| Crohn Disease | 1 |
| Inflammatory Bowel Diseases | 1 |
| Primary Lateral Sclerosis, Adult, 1 | 1 |
| Motor Neuron Disease | 1 |
| Papillon-Lefevre Disease | 1 |
| Cerebral Palsy | 1 |
| Muscle Spasticity | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Tax preparation firms in the United States](https://specstream.ai/data/businesses/tax-preparation-firms/united-states)
- [Furniture manufacturers in the United States](https://specstream.ai/data/businesses/furniture-manufacturers/united-states)
- [Trinidadian restaurants in the United States](https://specstream.ai/data/businesses/trinidadian-restaurants/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Warehouses in the United States](https://specstream.ai/data/businesses/warehouses/united-states)
